Research Article
Dennis M Marcus, Heather Frazi
Abstract
Background/objectives: To evaluate the safety and efficacy of aflibercept in eyes with persistent diabetic macular edema (DME) after treatment with bevacizumab and/or ranibizumab. Subjects/methods: Open-label, prospective study of intravitreal aflibercept injection in eyes with persistent DME after chronic, recent, and frequent bevacizumab and/or ranibizumab. Results: Thirty eyes were enrolled. Mean change in best corrected visual acuity (BCVA) from baseline to 52 weeks was +7 letters. The mean change in optical coherence tomography (OCT) central subfield thickness (CST) from baseline to 52 weeks was -118 um. At week 52, 70% of eyes with a baseline CST>350 um demonstrated>15% reduction in OCT CST. Forty-eight percent of eyes demonstrated no OCT evidence for DME at last visit. OCT-angiography demonstrated vascular density improvement in the deep capillary plexus. No significant ocular adverse events were observed. Conclusion: Aflibercept demonstrated beneficial visual and anatomic outcomes in patients with persistent DME following bevacizumab and/or ranibizumab.